Cell Therapeutics ($CTIC) appeals FDA decision on pixantrone

Cell Therapeutics said today that, as planned, it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory aggressive non-Hodgkin's lymphoma. Release